Chronic kidney disease (CKD) is a global health problem, affecting more than 850 million people worldwide. The number of patients receiving renal replacement therapy (dialysis or renal transplantation) has increased over the years, and it has been estimated that the number of people receiving renal replacement therapy will more than double from 2.618 million in 2010 to 5.439 million in 2030, with wide differences among countries. The main focus of CKD treatment has now become preserving renal function rather than replacing it. This is possible, at least to some extent, through the optimal use of multifactorial therapy aimed at preventing end-stage kidney disease and cardiovascular events. Sodium/glucose cotransporter 2 inhibitors (SGLT2i) reduce glomerular hypertension and albuminuria with beneficial effects on progression of renal damage in both diabetic and non-diabetic CKD. SGLT2 inhibitors also show great benefits in cardiovascular protection, irrespective of diabetes. Therefore, the use of these drugs will likely be extended to the whole CKD population as a new standard of care.

De Nicola, L., Cozzolino, M., Genovesi, S., Gesualdo, L., Grandaliano, G., Pontremoli, R. (2022). Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?. JN. JOURNAL OF NEPHROLOGY, 35(6), 1605-1618 [10.1007/s40620-022-01336-7].

Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?

Genovesi, Simonetta;
2022

Abstract

Chronic kidney disease (CKD) is a global health problem, affecting more than 850 million people worldwide. The number of patients receiving renal replacement therapy (dialysis or renal transplantation) has increased over the years, and it has been estimated that the number of people receiving renal replacement therapy will more than double from 2.618 million in 2010 to 5.439 million in 2030, with wide differences among countries. The main focus of CKD treatment has now become preserving renal function rather than replacing it. This is possible, at least to some extent, through the optimal use of multifactorial therapy aimed at preventing end-stage kidney disease and cardiovascular events. Sodium/glucose cotransporter 2 inhibitors (SGLT2i) reduce glomerular hypertension and albuminuria with beneficial effects on progression of renal damage in both diabetic and non-diabetic CKD. SGLT2 inhibitors also show great benefits in cardiovascular protection, irrespective of diabetes. Therefore, the use of these drugs will likely be extended to the whole CKD population as a new standard of care.
Articolo in rivista - Review Essay
CDK; Diabetes; ESKD; SGLT2i;
English
1605
1618
14
De Nicola, L., Cozzolino, M., Genovesi, S., Gesualdo, L., Grandaliano, G., Pontremoli, R. (2022). Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?. JN. JOURNAL OF NEPHROLOGY, 35(6), 1605-1618 [10.1007/s40620-022-01336-7].
De Nicola, L; Cozzolino, M; Genovesi, S; Gesualdo, L; Grandaliano, G; Pontremoli, R
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/385124
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
Social impact